Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,470 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
Parkville, VictoriaAges 2–17 - NCT05691218Recruiting
Early high-flow oxygen plus nebulized asthma medicine
This study tests whether giving fast, high-flow oxygen early—together with inhaled terbutaline via a vibrating mist—helps adults with moderate to severe asthma flare-ups in the emergency department. It aims to see if this approach improves breathing after initial treatment.
Poitiers, FranceAges 18 years+ - NCT05761028RecruitingPhase 2/Phase 3
CM310 for moderate to severe asthma despite current inhalers
This study tests CM310 to see if it can improve asthma in people with moderate to severe asthma who are still having uncontrolled symptoms and severe flare-ups despite regular inhaler treatment. You may be eligible if your lung function and asthma control tests fit the study limits and you’ve had a recent severe exacerbation.
Beijing, BeijinAges 12–75 - NCT06005103Recruiting
Testing a headband that sends brain pulses for depression
This study tests a new headband that sends gentle electrical pulses to the brain (T-PEMF) to lift depression. You might join if you have moderate to severe depression and don't have certain other conditions or implants.
Frederiksberg, Capital RegionAges 18–65 - NCT06258668Recruiting
Real-world study of Sotyktu for psoriasis in Korea
This study looks at how safe and effective a pill called Sotyktu is for people with moderate-to-severe plaque psoriasis in real-life medical settings in Korea. If you are 19 or older and are about to start Sotyktu for your psoriasis as your doctor prescribes, this study may be an option for you.
SeoulAges 19 years+ - NCT06425549RecruitingPhase 3
Bimekizumab vs. Ustekinumab for kids with plaque psoriasis
This study compares two medications—bimekizumab and ustekinumab—for children aged 6 to 17 with moderate-to-severe plaque psoriasis. It aims to see which one is more effective and safe in treating symptoms like thick, scaly patches on the skin.
Fountain Valley, CaliforniaAges 6–17 - NCT06456593RecruitingPhase 2
Obefazimod for moderate to severe Crohn's disease
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Fairhope, AlabamaAges 18–75 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT06560372Recruiting
Bleeding after head injury and brain blood vessel narrowing
This study looks at whether moderate to severe traumatic brain injury with bleeding around the brain can lead to a complication called cerebral vasospasm (narrowing of brain blood vessels). It's being done at Martinique University Hospital to understand how often this happens and how it affects recovery.
Fort-de-FranceAges 18 years+ - NCT06588855RecruitingPhase 3
Study of afimkibart for moderate to severe ulcerative colitis
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
Dothan, AlabamaAges 16–80 - NCT07690371RecruitingPhase 3
Study of rezpegaldesleukin for moderate to severe eczema
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
St. Petersburg, FloridaAges 12 years+ - NCT06696417Recruiting
Testing vunakizumab for moderate to severe plaque psoriasis
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
Shenyang, LiaoningAges 18 years+ - NCT06819891RecruitingPhase 3
Study of afimkibart for moderate to severe Crohn's disease
This trial tests a new medicine called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if it can reduce symptoms and improve quality of life.
Glendale, ArizonaAges 16–80 - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT06766357RecruitingPhase 3
Cyclosporin gel for moderate to severe dry eye
This study tests a gel form of cyclosporine for people with moderate to severe dry eye that hasn't improved with other treatments. The gel is applied to the eye to help reduce inflammation and increase tear production.
Xiamen, FujianAges 18 years+ - NCT06937944RecruitingPhase 3
New Botox-like injection for frown lines
This study tests a new botulinum toxin injection (similar to Botox) to see how well it smooths moderate to severe frown lines between the eyebrows. The treatment is given as a single injection and may help soften those lines for several months.
Beijing, Beijing MunicipalityAges 18–65 - NCT07098351Recruiting
A trial for a new itchy skin medicine for people on peritoneal dialysis
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
Guangzhou, GuangdongAges 18–85 - NCT07147049RecruitingPhase 2
Testing a new painkiller for moderate to severe pain after surgery
This trial tests a new tablet called HL-1186 for people with moderate to severe pain after certain surgeries. It aims to see if the drug is safe and works well for pain control.
Chengdu, SichuanAges 18–75 - NCT07169695RecruitingPhase 2
Comparing a new eye drop to cyclosporine for eye allergy in kids
This study tests a new eye drop (T1695) against cyclosporine for children with moderate to severe vernal keratoconjunctivitis, a type of eye allergy. It aims to see which treatment works better and is safer for reducing symptoms.
Kolkata, West BengalAges 4–17 - NCT07211542RecruitingPhase 2
Study of SHR-1905 for moderate-to-severe eczema
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07234591Recruiting
Study of an oral medication for moderate to severe plaque psoriasis
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
ShanghaiAges 18–70 - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80 - NCT07300384Recruiting
Blood flow restriction training for knee pain relief before surgery
This study tests whether a special type of strength training (called blood flow restriction training) can reduce pain in people with severe knee arthritis who are waiting for knee replacement surgery. The training uses a cuff on the thigh to lightly restrict blood flow while doing exercises until failure.
Valencia, ValenciaAges 50–85 - NCT07333118RecruitingEarly Phase 1
Testing GT801 for severe autoimmune diseases
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
Shanghai, Shanghai MunicipalityAges 18–65
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,470 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.